STORY AT-A-GLANCE

  • A preprint study led by Dr. Peter McCullough suggests using siRNA and RIBOTACs to target and degrade residual mRNA from COVID-19 vaccines, potentially mitigating long-term health risks associated with persistent spike protein production
  • COVID-19 mRNA vaccines have shown wider distribution in the body than initially claimed, raising concerns about unintended effects and the need for an “off switch” to stop ongoing spike protein production
  • The study proposes using siRNA and RIBOTACs as potential methods to bind to and degrade vaccine mRNA in cells, offering a targeted approach to prevent adverse events from mRNA-based therapies
  • “Long vax” symptoms, similar to long COVID, have been reported following vaccination, including fatigue, brain fog, numbness, and cardiovascular issues, highlighting the need for effective treatments for those affected
  • Another study led by McCullough found a significant increase in cerebral thromboembolism risk associated with COVID-19 vaccines compared to other vaccines, leading to calls for a moratorium on their use

https://articles.mercola.com/sites/articles/archive/2024/07/01/off-switch-covid-mrna-shots.aspx